|Description||Nesbuvir, a novel selective nonstructural protein 5B (NS5B) polymerase inhibitor, acts as candidate for HCV treatment. It was reduced across different isolates.|
Velpatasvir is a selective Hepatitis C virus NS 5 protein inhibitor originated by Gilead Sciences. It has showed pan-genotypic activity and a high barrier to re...
Peretinoin, also known as NIK-333, orally available, acyclic retinoid with potential antineoplastic and chemopreventive activities. Peretinoin binds to and acti...
Ribavirin is a guanosine (ribonucleic) analog used to stop viral RNA synthesis and viral mRNA capping, thus, it is a nucleoside inhibitor.
PSI-6206 (RO2433) is a selective HCV RNA polymerase inhibitor. It is the unphosphorylated parent compound of triphosphate analog PSI-7409, which is a potent inh...
PSI-7976 is an inhibitor of HCV RNA replication with EC50 value of 1.07μM. PSI-7851 is a phosphoramidate prodrug of PSI-7411 and has potent anti-hepatitis C vir...
VX-222 (VCH-222, Lomibuvir)
VX-222 (VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold ...
PSI-6130 is a potent and selective inhibitor of HCV NS5B polymerase. It is metabolized to two pharmacologically active species in primary human hepatocytes.
APC-6336 is a Hepatitis C virus NS3 protein inhibitor.
Tegobuvir is a non-nucleoside nonstructural protein (NS)5B polymerase inhibitor.
GSK-2818713 is a second-generation inhibitor of hepatitis C virus (HCV) NS5A replication. Compared to daclatasvir, a first-generation NS5A replication complex i...
Ombitasvir, a NS5A inhibitor, could be effective in the treatment of HCV as an antiviral agent. IC50: 14 pM and 5 pM (EC50) for genotype 1a-H77 and 1b-Con1 resp...
R-7128 is a selective nucleoside analog inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, with activity across all HCV genotypes. It i...
In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical stu...
Beclabuvir is a potent, non-nucleotide inhibitor of HCV NS5B which is currently in Phase III clinical trials for the treatment of chronic HCV infection. Beclabu...
Nesbuvir, a novel selective nonstructural protein 5B (NS5B) polymerase inhibitor, acts as candidate for HCV treatment. It was reduced across different isolates.
An NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection.
Elbasvir has been found to restrain viral phosphoprotein so that could be used against hepatitis C virus and is currently under Phase II trail.
ACH-806 is a Hepatitis C virus NS3 protein inhibitor. It can inhibit viral RNA replication in HCV replicon cells and is active in genotype 1 HCV-infected patien...
Ciluprevir is used experimentally in the treatment of hepatitis C. It is manufactured by Boehringer Ingelheim Pharma GmbH & Co. kg and developed under the resea...
PSI-7409, the active 5′-triphosphate metabolite of PSI-7851, is a potent inhibitor of the HCV NS5B RNA dependent RNA polymerase.